Arcutis Biotherapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Arcutis Biotherapeutics (US): 1 reconciled FDA prescription therapies, $53.3M 2024 CMS Part D & Medicaid spend, and $965 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2037-01-01
2024 CMS Total Public Spend$53.3M
2024 Medicare Part D Spend$25.6M
2024 Medicaid Spend$27.7M
California HCAI SB 17 FilingsSpecialty launch notice ($965 intro WAC)